Merck Buying Drug Targeting B-Cell Diseases for Up to $1.3 Billion; Merck will acquire full global rights to clinical-stage bispecific antibody CN201 from Curon Biopharmaceutical

Saved in:
Bibliographic Details
Published in:The Wall Street journal. Eastern edition 2024-08-09
Main Author: Kellaher, Colin
Format: Newspaper Article
Language:English
Subjects:
Regulatory approval
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2574-9579